Wainberg, Zev A.

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology

Cancer Immunotherapy and BiomarkersGastric Cancer Management and Outcomes

Cited by 1,784

Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer

Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., Curiel, T. J., Colon-Otero, G., Hamid, O., Sanborn, R. E., et al. (2016) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 840

Structure-guided blockade of CSF1R kinase in tenosynovial giant-cell tumor

Tap, W. D., Wainberg, Z. A., Anthony, S. P., Ibrahim, P. N., Zhang, C., Healey, J. H., Chmielowski, B., Staddon, A. P., Cohn, A. L., Shapiro, G. I., et al. (2015) · New England Journal of Medicine

Musculoskeletal synovial abnormalities and treatmentsRheumatoid Arthritis Research and Therapies

Cited by 582

Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial

Padrón, L. J., Maurer, D. M., O’Hara, M. H., O’Reilly, E. M., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., et al. (2022) · Nature Medicine

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 384

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Gazzah, A., Lassen, U., Stein, A., Wen, P. Y., Dietrich, S., de Jonge, M. J. A., Blay, J.-Y., et al. (2023) · Nature Medicine

Melanoma and MAPK PathwaysGastrointestinal Tumor Research and Treatment

Cited by 343

A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors

Bedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Van Cutsem, E., Pérez-García, J., Stathis, A., Britten, C. D., et al. (2015) · Clinical Cancer Research

PI3K/AKT/mTOR signaling in cancerAdvanced Breast Cancer Therapies

Cited by 324

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

O'Hara, M. H., O'Reilly, E. M., Varadhachary, G., Wolff, R. A., Wainberg, Z. A., Ko, A. H., Fisher, G., Rahma, O., Lyman, J. P., Cabanski, C. R., et al. (2021) · The Lancet Oncology

Pancreatic and Hepatic Oncology ResearchCancer Immunotherapy and Biomarkers

Cited by 307

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial

Pant, S., Wainberg, Z. A., Weekes, C. D., Furqan, M., Kasi, P. M., Devoe, C. E., Leal, A. D., Chung, V., Basturk, O., VanWyk, H., et al. (2024) · Nature Medicine

Immunotherapy and Immune ResponsesPancreatic and Hepatic Oncology Research

Cited by 267

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer

van Geel, R. M. J. M., Tabernero, J., Elez, E., Bendell, J. C., Spreafico, A., Schuler, M., Yoshino, T., Delord, J.-P., Yamada, Y., Lolkema, M. P., et al. (2017) · Cancer Discovery

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 232

Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications

Colorectal Cancer Treatments and StudiesHER2/EGFR in Cancer Research

Cited by 178

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

O’Reilly, E. M., Wainberg, Z. A., Hendifar, A. E., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P., Cremolini, C., Manji, G. A., Oberstein, P. E., et al. (2026) · New England Journal of Medicine

Pancreatic and Hepatic Oncology ResearchColorectal Cancer Treatments and Studies

Cited by 147

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

Wainberg, Z. A., Alsina, M., Soares, H. P., Braña, I., Britten, C. D., Del Conte, G., Ezeh, P., Houk, B., Kern, K. A., Leong, S., et al. (2017) · Targeted Oncology

PI3K/AKT/mTOR signaling in cancerColorectal Cancer Treatments and Studies

Cited by 98

Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT)

Wainberg, Z. A., Enzinger, P. C., Kang, Y.-K., Yamaguchi, K., Qin, S., Lee, K.-W., Oh, S. C., Li, J., Turk, H. M., Teixeira, A. C., et al. (2021) · Journal of Clinical Oncology

Gastric Cancer Management and OutcomesFibroblast Growth Factor Research

Cited by 76

First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.

Pant, S., Furqan, M., Abdul-Karim, R. M., Chung, V., Devoe, C. E., Johnson, M. L., Leal, A. D., Park, H., Wainberg, Z. A., Welkowsky, E., et al. (2022) · Journal of Clinical Oncology

Immunotherapy and Immune ResponsesPancreatic and Hepatic Oncology Research

Cited by 28

Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).

Tabernero, J., Van Cutsem, E., Prausová, J., Isambert, N., Neuzillet, C., Siena, S., Pietrantonio, F., Falk, S., Wainberg, Z. A., Raghav, K. P. S., et al. (2021) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 4

Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer

Van Cutsem, E., Yaeger, R., Delord, J.-P., Tabernero, J., Siu, L. L., Ducreux, M., Siena, S., Elez, E., Kasper, S., Zander, T., et al. (2023) · The Oncologist

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 3